NEW YORK (GenomeWeb News) – Nuevolution said today that it will use its DNA labeling platform to identify small-molecule leads against drug targets in a collaboration with Merck.
 
Copenhagen-based Nuevolution said it will use its Chemetics platform to screen multi-million member libraries for hit identification, and to perform hit-to-lead optimization.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.